
Kohjin Bio Co., Ltd.
177A.TJPXHealthcareBiotechnology
最新数据
JP¥845
−JP¥1.00 · -0.12%
177A.T公司概览
盘中时间采用JST。市场数据可能有所延迟。
公司概况
公司网站Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materials, including animal blood, sera, cell culture media, agar media for microbial assays, in-vitro diagnostic products, and cosmetics. Its extensive catalog for cell and tissue culture features specialized mediums crucial for virus and recombinant protein synthesis, hybridoma development, human lymphocyte cultivation, and insect cell lines. Additionally, Kohjin Bio supplies complementary items such as gas-permeable cell culture bags, cryopreservation agents, medium supplements, normal human cells along with their growth media, ES cell media, and comprehensive kits for in-vitro fertilization and early embryo culture. The firm further provides essential laboratory tools like cell separation solutions, physiological salt solutions, and a range of research reagents. Within microbiology, Kohjin Bio offers a wide array of culture media tailored for various applications. For clinical diagnostics, this includes mediums for identifying gram-positive cocci and gram-negative bacteria, susceptibility testing, general differentiation, anaerobic growth, and fungal detection, alongside tube mediums for confirmatory tests and expansion. For food safety, their products cover sterilization assessments, and the detection of E. coli, coliform bacteria, Staphylococcus spp., Bacillus cereus, and Vibrio parahaemolyticus. The company also produces mediums for total viable cell count determination and specific media for Campylobacter and fungi. The company's blood and serum division offers normal human blood, serum, and plasma, as well as pathological human serum. Its animal blood portfolio encompasses preserved, defibrinated, and hemolyzed animal blood, in addition to animal serum and plasma, with custom-designed formulations like Eagle medium also available. Beyond its manufacturing activities, Kohjin Bio engages in the breeding and distribution of laboratory animals, the sale of medical equipment, and provides contract services for animal immunization and antibody preparation. The company also manages the import and export of its diverse products and raw materials internationally.
- 行业
- Biotechnology
- 部门
- Healthcare
- 总部
- JP
- 首席执行官
- Takahito Nakamura
- 上市以来
- 2024年4月25日
- 雇员
- 176
市场位置
52周区间
当前JP¥845,
- 开盘价
- JP¥845
- 前收盘价
- JP¥846
- 成交量
- 1800
- 0.15× 平均值
- 平均成交量
- 1.19万
- 日均成交量
- 市值
- 43.19亿 JPY
- 贝塔
- 0
- 市场参考 1
- 50天平均值
- JP¥906.24
- 低于平均水平-6.76%
- 200天平均值
- JP¥1,235.57
- 低于平均水平-31.61%
财务数据
财务快照
最近十二个月估值与收益率
- 企业价值
- 58.9亿 JPY
- 市盈率(TTM)
- 34.06×
- 市净率(TTM)
- 0.73×
- 市销率(TTM)
- 0.92×
- EV/EBITDA
- 7.69×
- 盈利收益率
- 4.06%
- 自由现金流收益率
- -4.54%
- 股息率
- 1.18%
盈利能力和效率
- 毛利率
- 35.65%
- 营业利润率
- 3.32%
- 净利润率
- 2.70%
- 净资产收益率
- 4.22%
- 资产收益率
- 2.82%
- 投入资本回报率
- 3.13%
财务健康
- 负债权益比
- 0.31×
- 流动比率
- 1.8×
- 奥特曼 Z 分数
- 2.27
- 皮奥特罗斯基 F 分数
- 3 共 9 个
财务报表
利润率趋势
盈利能力占已公布营收的百分比。
损益趋势
营收
营业利润
净利润
| 项目(JPY) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 49.39亿 JPY | 52.06亿 JPY | 47.7亿 JPY | 47.43亿 JPY | 39.47亿 JPY |
| 销货成本 | 30.82亿 JPY | 28.4亿 JPY | 28.89亿 JPY | 22.89亿 JPY | 19.08亿 JPY |
| 毛利 | 18.57亿 JPY | 23.66亿 JPY | 18.81亿 JPY | 24.54亿 JPY | 20.39亿 JPY |
| 销售、一般及管理费用 | 15.16亿 JPY | — | −1000 JPY | 11.86亿 JPY | 10.69亿 JPY |
| 营业费用 | 15.16亿 JPY | 13.75亿 JPY | 12.84亿 JPY | 11.87亿 JPY | 10.7亿 JPY |
| 利息收入 | 441.8万 JPY | 193.2万 JPY | 65.1万 JPY | 42.5万 JPY | 27.3万 JPY |
| 利息支出 | 3805.4万 JPY | 3007.1万 JPY | 2287.2万 JPY | 3246.6万 JPY | 3894万 JPY |
| 折旧和摊销 | 3.96亿 JPY | 3.61亿 JPY | 3亿 JPY | 1.68亿 JPY | 1.79亿 JPY |
| 营业利润 | 3.42亿 JPY | 9.91亿 JPY | 5.97亿 JPY | 12.67亿 JPY | 9.7亿 JPY |
| 净利润 | 2.51亿 JPY | 7.95亿 JPY | 3.84亿 JPY | 8.3亿 JPY | 5.88亿 JPY |
公司数据更新于 2026年8月24日。
财报历史与展望
- 最新每股收益结果
- -8.2
EPS:实际值与预期值
近期已公布业绩
营收:实际值与预期值
近期已公布业绩
177A.T同业公司
继续GoAI的研究
在 GoAI 中研究177A.Tresearch.disclaimer





